Immunogen Inc
IMGN
IMGN was delisted on the 9th of February, 2024.
214 hedge funds and large institutions have $1.18B invested in Immunogen Inc in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 59 reducing their positions, and 35 closing their positions.
1,099% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $1.07M
14% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 59
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 35
1% less funds holding
Funds holding: 217 → 214 (-3)
20% less capital invested
Capital invested by funds: $1.48B → $1.18B (-$294M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$26.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17.4M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$17.2M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$16.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$45.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.8M |
| 3 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$15M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.4M |
| 5 |
Goldman Sachs
New York
|
-$8.64M |
IMGN Hedge Fund Activity: Q2 2021 in Review
214 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2021, worth a combined $1.18B — down 20% from $1.48B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of IMGN and 33 opened new positions — a net loss of 2 holders — while 59 trimmed existing stakes and 67 added.
The largest buyer was OrbiMed, adding an estimated $26.5M. The largest seller was Ameriprise, exiting entirely with an estimated $45.3M sold.
- 214 institutional investors held Immunogen Inc (IMGN) as of Q2 2021, down from 217 in Q1 2021.
- Funds reported $1.18B of Immunogen Inc stock for Q2 2021, down 20% quarter-over-quarter.
- 33 funds opened new Immunogen Inc positions in Q2 2021 and 35 closed out, a net change of -2 holders.
- The largest Immunogen Inc buyer in Q2 2021 was OrbiMed, an estimated $26.5M added.
- The largest Immunogen Inc seller in Q2 2021 was Ameriprise, an estimated $45.3M sold.
Based on aggregated 13F filings for Q2 2021.